Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$115.95 USD
-2.68 (-2.26%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $115.96 +0.01 (0.01%) 7:54 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Return on Equity (TTM)
Axsome Therapeutics, Inc.'s return on equity, or ROE, is -283.22% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that AXSM has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
AXSM 115.95 -2.68(-2.26%)
Will AXSM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXSM
Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates
Other News for AXSM
Technical picture remains unchanged for AXSM after it rises 1.72% on September 18
Axsome Therapeutics: Strong Growth Trajectory and Financial Outlook Justify Buy Rating
Axsome Therapeutics, Inc. (AXSM) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript
AXSM's price rises by 2.21% on September 18, though its technical setup remains stable.
Fairmount Funds Management LLC Increases Stake in Dianthus Therapeutics Inc